Welcome to our dedicated page for Aurinia Pharmaceuticals news (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmaceuticals stock.
Aurinia Pharmaceuticals Inc (symbol: AUPH) is a cutting-edge biopharmaceutical company headquartered at 5120-75 street, Edmonton, Canada. Specializing in the treatment of serious diseases with high unmet medical need, Aurinia is committed to providing innovative therapeutic solutions to patients worldwide. The company's flagship product, LUPKYNIS (voclosporin), is an investigational drug designed for the treatment of lupus nephritis (LN), a severe renal complication of lupus. This groundbreaking treatment underscores Aurinia's focus on developing life-changing medications.
In recent years, Aurinia Pharmaceuticals has made significant strides in its research and development efforts, particularly in the United States, where it derives the majority of its revenue. The company has forged strategic partnerships with leading healthcare organizations and continues to explore new avenues for growth and innovation.
Financially, Aurinia has demonstrated strong performance, with consistent revenue growth driven by its robust pipeline of investigational drugs. The company's commitment to advancing its clinical programs and securing regulatory approvals positions it well for sustained success in the biopharmaceutical industry.
With a dedicated team of experts and a clear vision for the future, Aurinia Pharmaceuticals is poised to make a lasting impact on global healthcare. Investors and stakeholders can stay updated on the latest developments, financial results, and strategic initiatives through the company's regular news updates and investor relations communications.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reported preliminary unaudited net revenues of approximately
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that Peter Greenleaf, CEO, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11 at 4:30 p.m. PT in San Francisco, CA. Interested parties can listen to the live audio webcast on the Aurinia corporate website under the 'News/Events' section. Aurinia is dedicated to developing therapies for serious diseases, having launched LUPKYNIS®, the first FDA-approved oral treatment for active lupus nephritis in January 2021.
Aurinia Pharmaceuticals (NASDAQ: AUPH) and Sun Pharmaceuticals have reached a settlement regarding patent infringement claims related to Sun's CEQUA® product. The settlement includes a joint motion to dismiss an Inter Partes Review of Aurinia's U.S. Patent No. 10,286,036. This agreement is contingent on the U.S. Patent Trial and Appeal Board terminating the Inter Partes Review. Both companies will cease further claims against each other under this settlement.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced the grant of inducement stock options and restricted stock units (RSUs) to two new employees. A total of 36,220 stock options were issued, with an exercise price of $5.10, alongside 22,120 RSUs, all dated December 5, 2022. The options vest over three years, while the RSUs vest in equal annual installments over three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to support the company's mission in autoimmune disease therapeutics.
Aurinia Pharmaceuticals has received marketing authorization for LUPKYNIS (voclosporin) from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with active lupus nephritis (LN). This approval follows the European Commission's authorization on September 19, 2022, highlighting the drug's promising phase 3 clinical trial outcomes. LUPKYNIS is the first oral medication approved in both the U.S. and Europe for LN, aiming to improve treatment accessibility for patients.
Aurinia Pharmaceuticals announced Q3 2022 net revenue of $55.8 million, up from $14.7 million in Q3 2021. The revenue includes a $30 million milestone from Otsuka for LUPKYNIS® approval in Europe. The company adjusted its revenue guidance for 2022 to $100-105 million and projected $120-140 million for 2023. As of October 31, 2022, Aurinia reported approximately $400 million in cash and equivalents. Despite a slight decline in new patient start forms, the company achieved significant progress in commercialization and patient adherence.
Aurinia Pharmaceuticals announced it will release its third quarter 2022 financial and operational results on November 3, 2022, before market opening. The company’s management will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update. Participants can join the call by dialing 877-407-9170 (U.S. and Canada) or via the company’s website. Aurinia is known for its FDA-approved treatment LUPKYNIS® for lupus nephritis, aiming to meet high medical needs in targeted patient populations.
Aurinia Pharmaceuticals (NASDAQ:AUPH) announced that data from various studies of LUPKYNIS® (voclosporin) will be presented at the American Society of Nephrology (ASN) Kidney Week 2022 in Orlando, Florida, from November 3-6. The presentations will highlight LUPKYNIS's long-term safety and efficacy in treating active lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE). Notable studies include efficacy over three years and a prospective registry of patients treated with voclosporin.
Aurinia Pharmaceuticals (NASDAQ:AUPH) announced the granting of inducement stock options and restricted stock units (RSUs) to four new employees. A total of 20,800 stock options priced at $7.52 per share and 12,500 RSUs were granted, effective October 3, 2022. The stock options vest over three years, with one-third vesting after one year, while the RSUs vest in three annual installments. This opportunity is aligned with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent critical to the company’s mission of addressing autoimmune diseases.
Aurinia Pharmaceuticals announced five abstracts on the long-term safety and efficacy of voclosporin, particularly for Latino patients with Class V lupus nephritis, ahead of ACR Convergence 2022 in Philadelphia from November 10-14. The presentations highlight voclosporin’s effectiveness in managing proteinuria and its safety over extended use. Aurinia also emphasized its commitment to autoimmune disease treatment with a focus on AUR200, a pre-clinical asset. This reinforces the company's strategic position in the lupus nephritis treatment market.
FAQ
What is the current stock price of Aurinia Pharmaceuticals (AUPH)?
What is the market cap of Aurinia Pharmaceuticals (AUPH)?
What does Aurinia Pharmaceuticals Inc. specialize in?
Where is Aurinia Pharmaceuticals Inc. located?
What is LUPKYNIS (voclosporin)?
Where does Aurinia Pharmaceuticals derive most of its revenue?
What recent achievements has Aurinia Pharmaceuticals accomplished?
How can investors stay updated on Aurinia Pharmaceuticals' latest news?
What is the significance of LUPKYNIS for Aurinia Pharmaceuticals?
What type of diseases does Aurinia Pharmaceuticals focus on?
Has Aurinia Pharmaceuticals formed any partnerships?